Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fresenius SE & Co. KGaA (FRE.DE)
Bad Homburg vor der Höhe, DE
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.90% | -0.93% | -11.59% | -21.56% | -20.59% | -17.30% | -7.88% | +42.93% | -10.12% | -38.03% | +69.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | +1 |
| Buy | 8 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+4.8% Q1'26: +3.0% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+166.7% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+6.2% Q1'26: +2.7% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+9.5% Q1'26: +10.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+5.3% Q1'26: +6.4% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×3.62× Q1'26: 3.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 10 EPS Ana. |
Dec 2027 13 Rev. Ana. 11 EPS Ana. |
Dec 2028 10 Rev. Ana. 7 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.52B
est: 16.80B (-1.7%)
|
19.51B
est: 19.52B (0.0%)
|
20.55B
est: 20.71B (-0.8%)
|
23.46B
est: 23.49B (-0.1%)
|
28.00B
est: 27.75B (+0.9%)
|
29.47B
est: 29.15B (+1.1%)
|
33.89B
est: 33.96B (-0.2%)
|
33.53B
est: 33.37B (+0.5%)
|
35.41B
est: 35.40B (+0.0%)
|
36.28B
est: 36.18B (+0.3%)
|
37.08B
est: 37.34B (-0.7%)
|
21.33B
est: 40.90B (-47.8%)
|
21.07B
est: 22.63B (-6.9%)
|
21.83B
est: 21.59B (+1.1%)
|
22.87B
est: 22.52B (+1.6%)
|
23.65B
23.48B – 23.83B
+5.0% YoY
|
24.87B
24.47B – 25.37B
+5.1% YoY
|
26.09B
26.09B – 26.10B
+4.9% YoY
|
27.59B
27.27B – 27.97B
+5.7% YoY
|
29.02B
28.68B – 29.42B
+5.2% YoY
|
| EBITDA |
3.22B
est: 1.34B (+139.1%)
|
3.77B
est: 1.67B (+126.0%)
|
3.78B
est: 1.95B (+94.3%)
|
4.00B
est: 2.24B (+78.9%)
|
5.04B
est: 2.55B (+97.8%)
|
5.48B
est: 3.02B (+81.4%)
|
5.82B
est: 3.71B (+56.7%)
|
5.71B
est: 3.45B (+65.7%)
|
6.73B
est: 4.10B (+64.3%)
|
6.86B
est: 4.68B (+46.6%)
|
6.25B
est: 4.94B (+26.4%)
|
2.65B
est: 5.18B (-48.7%)
|
2.74B
est: 3.20B (-14.4%)
|
3.04B
est: 3.11B (-2.3%)
|
3.30B
est: 3.18B (+3.7%)
|
3.34B
3.32B – 3.37B
+5.0% YoY
|
3.51B
3.46B – 3.58B
+5.1% YoY
|
3.69B
3.68B – 3.69B
+4.9% YoY
|
3.90B
3.85B – 3.95B
+5.7% YoY
|
4.10B
4.05B – 4.16B
+5.2% YoY
|
| EBIT |
2.54B
est: 2.51B (+1.1%)
|
2.98B
est: 2.98B (+0.2%)
|
2.88B
est: 3.18B (-9.5%)
|
3.04B
est: 3.34B (-9.0%)
|
3.91B
est: 3.73B (+4.8%)
|
4.27B
est: 4.14B (+3.1%)
|
4.38B
est: 4.93B (-11.2%)
|
4.22B
est: 4.55B (-7.4%)
|
4.32B
est: 5.54B (-22.0%)
|
4.14B
est: 4.86B (-14.7%)
|
3.60B
est: 5.13B (-29.9%)
|
1.50B
est: 5.37B (-72.1%)
|
1.34B
est: 1.86B (-28.0%)
|
1.84B
est: 5.96B (-69.2%)
|
2.18B
est: 1.85B (+17.9%)
|
1.94B
1.93B – 1.95B
+5.0% YoY
|
2.04B
2.01B – 2.08B
+5.1% YoY
|
2.14B
2.14B – 2.14B
+4.9% YoY
|
2.26B
2.24B – 2.29B
+5.7% YoY
|
2.38B
2.35B – 2.41B
+5.2% YoY
|
| Net Income |
690.00M
est: 645.74M (+6.9%)
|
932.00M
est: 801.49M (+16.3%)
|
988.00M
est: 990.32M (-0.2%)
|
1.07B
est: 1.12B (-4.5%)
|
1.39B
est: 1.28B (+8.1%)
|
1.56B
est: 1.46B (+7.0%)
|
1.81B
est: 1.79B (+1.4%)
|
2.03B
est: 1.80B (+12.6%)
|
1.88B
est: 2.14B (-11.9%)
|
1.71B
est: 1.97B (-13.6%)
|
1.82B
est: 2.09B (-12.9%)
|
1.37B
est: 2.19B (-37.2%)
|
-594.00M
est: 721.00M (-182.4%)
|
471.00M
est: 1.65B (-71.5%)
|
1.26B
est: 1.95B (-35.1%)
|
1.90B
1.86B – 2.12B
-2.4% YoY
|
2.13B
2.02B – 2.28B
+11.9% YoY
|
2.33B
2.08B – 2.63B
+9.5% YoY
|
2.68B
2.64B – 2.73B
+15.2% YoY
|
2.93B
2.89B – 2.98B
+9.3% YoY
|
| SGA |
2.83B
est: 2.77B (+2.1%)
|
3.23B
est: 3.26B (-1.1%)
|
3.33B
est: 3.43B (-2.7%)
|
3.67B
est: 3.71B (-1.1%)
|
4.57B
est: 4.54B (+0.5%)
|
4.74B
est: 4.84B (-2.1%)
|
5.54B
est: 5.56B (-0.4%)
|
4.95B
est: 5.51B (-10.2%)
|
5.37B
est: 5.14B (+4.4%)
|
5.43B
est: 5.67B (-4.3%)
|
5.44B
est: 5.99B (-9.3%)
|
3.09B
est: 6.27B (-50.8%)
|
3.03B
est: 3.14B (-3.7%)
|
2.90B
est: 3.06B (-5.1%)
|
2.88B
est: 3.13B (-7.8%)
|
3.28B
3.26B – 3.31B
+5.0% YoY
|
3.45B
3.40B – 3.52B
+5.1% YoY
|
3.62B
3.62B – 3.62B
+4.9% YoY
|
3.83B
3.78B – 3.88B
+5.7% YoY
|
4.03B
3.98B – 4.08B
+5.2% YoY
|
| EPS |
1.41
est: 1.54 (-8.2%)
|
1.80
est: 1.80 (-0.1%)
|
1.84
est: 1.95 (-5.6%)
|
1.98
est: 2.03 (-2.5%)
|
2.55
est: 2.62 (-2.5%)
|
2.86
est: 2.91 (-1.8%)
|
3.27
est: 3.32 (-1.6%)
|
3.65
est: 3.31 (+10.3%)
|
3.38
est: 3.32 (+1.9%)
|
3.06
est: 3.20 (-4.5%)
|
3.26
est: 3.30 (-1.1%)
|
2.44
est: 3.06 (-20.3%)
|
-1.05
est: 1.28 (-182.0%)
|
0.84
est: 2.93 (-71.3%)
|
2.24
est: 3.45 (-35.1%)
|
3.58
3.31 – 3.77
+3.8% YoY
|
3.88
3.58 – 4.04
+8.4% YoY
|
4.29
3.69 – 4.67
+10.3% YoY
|
4.76
4.69 – 4.84
+11.0% YoY
|
5.20
5.12 – 5.30
+9.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Sen | Chief Executive Officer, President & Chairman of Management Board of Fresenius Management SE | 5M | male |
| Pierluigi Antonelli | Member of Management Board of Fresenius Management SE & Chief Executive Officer of Fresenius Kabi | 2M | male |
| Sara Hennicken | Chief Financial Officer & Member of the Management Board - Fresenius Management SE | 2M | female |
| Michael Sven Moser | Member of the Management Board of Fresenius Management SE | 2M | — |
| Robert Moller | Member of the Management Board of Fresenius Management SE | 2M | male |
| Nick Stone | Senior Vice President of Investor Relations & Head of Investor Relations - Fresenius Management SE | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FRE.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
